Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake

Rhea-AI Filing Summary

Wasatch Advisors reports beneficial ownership of 1,930,185 Esperion Therapeutics shares, representing 0.7% of the company’s stock class. The position carries sole voting power and sole dispositive power over all of these shares, with no shared voting or dispositive authority.

The disclosure characterizes this stake as “Ownership of 5 percent or less of a class,” indicating that Wasatch Advisors holds a relatively small fraction of Esperion’s outstanding stock.

Key Figures

Beneficial ownership: 1,930,185 shares Percent of class: 0.7 % Sole voting power: 1,930,185 shares +1 more

4 metrics

Beneficial ownership 1,930,185 shares Shares of Esperion stock beneficially owned by Wasatch Advisors

Percent of class 0.7 % Portion of Esperion’s stock class owned by Wasatch Advisors

Sole voting power 1,930,185 shares Shares over which Wasatch Advisors has sole power to vote

Sole dispositive power 1,930,185 shares Shares over which Wasatch Advisors has sole power to dispose

Key Terms

beneficially owned, sole power to vote, sole power to dispose or to direct the disposition of, Ownership of 5 percent or less of a class

4 terms

beneficially owned financial

"Amount beneficially owned: 1,930,185"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole power to vote financial

"Sole power to vote or to direct the vote: 1,930,185"

sole power to dispose or to direct the disposition of financial

"Sole power to dispose or to direct the disposition of: 1,930,185"

Ownership of 5 percent or less of a class financial

"Ownership of 5 percent or less of a class"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 05:09 PM Accepted by SEC EDGAR 07/14/2026 - 05:08 PM Learn about SEC filing dates

FAQ

What stake does Wasatch Advisors report in Esperion Therapeutics (ESPR)?

Wasatch Advisors reports beneficial ownership of 1,930,185 Esperion shares. This holding represents 0.7% of the company’s stock class, with the entire position reported as beneficially owned under Schedule 13G/A for Esperion Therapeutics.

What percentage of Esperion Therapeutics (ESPR) stock does Wasatch Advisors own?

Wasatch Advisors reports owning 0.7% of Esperion’s stock class. This percentage is based on 1,930,185 shares of ESPR that the firm identifies as beneficially owned in its Schedule 13G/A Amendment No. 1.

Does Wasatch Advisors have sole or shared voting power over its ESPR shares?

Wasatch Advisors reports sole voting power over 1,930,185 Esperion shares and no shared voting power. The same 1,930,185 shares are also reported with sole dispositive power, meaning only Wasatch directs how they may be voted or disposed.

What does “Ownership of 5 percent or less of a class” mean for ESPR in this report?

The report labels Wasatch Advisors’ Esperion position as “Ownership of 5 percent or less of a class.” This reflects that its 0.7% stake in ESPR stock is well below the 5% level referenced in the ownership classification section.

Where is Wasatch Advisors, the ESPR shareholder, organized and based?

Wasatch Advisors is described as a Delaware entity with its principal business office at 505 Wakara Way, 3rd Floor, Salt Lake City, 84108, United States. This information accompanies its reported ownership of Esperion Therapeutics shares.

What class of Esperion (ESPR) securities does Wasatch Advisors hold and what is the CUSIP?

Wasatch Advisors reports holding Esperion’s COM class of securities, identified by CUSIP 29664W105. All 1,930,185 shares disclosed in the filing relate to this single class of Esperion stock.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Esperion Therapeutics Inc

(Name of Issuer)

COM

(Title of Class of Securities)

29664W105

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29664W105

1

Names of Reporting Persons

Wasatch Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,930,185.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,930,185.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,930,185.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Esperion Therapeutics Inc
(b)	Address of issuer's principal executive offices: 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108
Item 2.
(a)	Name of person filing: Wasatch Advisors LP
(b)	Address or principal business office or, if none, residence: 505 Wakara Way, 3rd Floor, Salt Lake City, 84108, United States
(c)	Citizenship: DELAWARE
(d)	Title of class of securities: COM
(e)	CUSIP No.: 29664W105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,930,185
(b)	Percent of class: 0.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,930,185
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,930,185
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Wasatch Advisors LP

Signature:	Mike Yeates
Name/Title:	CEO
Date:	07/14/2026